New Protein MRI Contrast Agent Developed for Liver Cancer Imaging
By MedImaging International staff writers Posted on 01 Jun 2015 |
The results of a study published in the May, 13, 2015, online issue of the Proceedings of the National Academy of Sciences of the United States of America (PNAS) reveal the development of a novel, and much more effective Magnetic Resonance Imaging (MRI) contrast agent, named ProCA32.
The researchers from the Georgia State University (Atlanta, GA, USA) and other institutions in Atlanta anticipate that the new protein-based MRI contrast agent and associated imaging methodology could help earlier detection of liver cancer, and other liver diseases. Existing contrast agents and imaging techniques are not sensitive and robust enough to diagnose primary and metastatic liver cancers early enough, and show poor treatment responses, and result in high mortality rates.
ProCA32 shows high stability for Gadolinium (Gd3+) and a 1011-times increased selectivity for Gd3+ over Zinc (Zn2+) compared with existing contrast agents, and can be used to detect early-stage micro-metastatic liver tumors. Using T1- and T2-weighted and T2/T1 ratio robust MRI imaging, the researchers were able to detect early liver metastases ∼0.24 mm in diameter. The current detection size limit is 10–20 mm.
The new contrast agent has additional properties that make it suitable for high-quality imaging, and could be a breakthrough, not only for early detection of primary and metastatic liver cancers, but also for treatment monitoring, and guiding therapeutic interventions, such as drug delivery.
Related Links:
Georgia State University
The researchers from the Georgia State University (Atlanta, GA, USA) and other institutions in Atlanta anticipate that the new protein-based MRI contrast agent and associated imaging methodology could help earlier detection of liver cancer, and other liver diseases. Existing contrast agents and imaging techniques are not sensitive and robust enough to diagnose primary and metastatic liver cancers early enough, and show poor treatment responses, and result in high mortality rates.
ProCA32 shows high stability for Gadolinium (Gd3+) and a 1011-times increased selectivity for Gd3+ over Zinc (Zn2+) compared with existing contrast agents, and can be used to detect early-stage micro-metastatic liver tumors. Using T1- and T2-weighted and T2/T1 ratio robust MRI imaging, the researchers were able to detect early liver metastases ∼0.24 mm in diameter. The current detection size limit is 10–20 mm.
The new contrast agent has additional properties that make it suitable for high-quality imaging, and could be a breakthrough, not only for early detection of primary and metastatic liver cancers, but also for treatment monitoring, and guiding therapeutic interventions, such as drug delivery.
Related Links:
Georgia State University
Latest Nuclear Medicine News
- New PET Agent Rapidly and Accurately Visualizes Lesions in Clear Cell Renal Cell Carcinoma Patients
- New Imaging Technique Monitors Inflammation Disorders without Radiation Exposure
- New SPECT/CT Technique Could Change Imaging Practices and Increase Patient Access
- New Radiotheranostic System Detects and Treats Ovarian Cancer Noninvasively
- AI System Automatically and Reliably Detects Cardiac Amyloidosis Using Scintigraphy Imaging
- Early 30-Minute Dynamic FDG-PET Acquisition Could Halve Lung Scan Times
- New Method for Triggering and Imaging Seizures to Help Guide Epilepsy Surgery
- Radioguided Surgery Accurately Detects and Removes Metastatic Lymph Nodes in Prostate Cancer Patients
- New PET Tracer Detects Inflammatory Arthritis Before Symptoms Appear
- Novel PET Tracer Enhances Lesion Detection in Medullary Thyroid Cancer
- Targeted Therapy Delivers Radiation Directly To Cells in Hard-To-Treat Cancers
- New PET Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Algorithm Predicts Prostate Cancer Recurrence in Patients Treated by Radiation Therapy
- Novel PET Imaging Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Ultrafast Laser Technology to Improve Cancer Treatment
- Low-Dose Radiation Therapy Demonstrates Potential for Treatment of Heart Failure